| Cvs Pharmacy # 02595 | |
| 722 Dutchess Tpke, Poughkeepsie, New York 12603 | |
| (845) 452-7117 |
| Name | Cvs Pharmacy # 02595 |
|---|---|
| Organization Name | Cvs Albany Llc |
| Location | 722 Dutchess Tpke, Poughkeepsie, New York 12603 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (845) 452-7117 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
Included in the 2012 International Antiviral Society-USA panel recommendations for human immunodeficiency virus (HIV) patient care is that all adult patients, regardless of CD4 cell count, should be offered antiretroviral therapy (ART), according to an article in the July 25 issue of JAMA, a theme issue on HIV/AIDS.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, today will participate in the first international bell-ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and future challenges in the battle to eradicate polio at the stock exchanges in New York, Paris, Brussels, Amsterdam and Lisbon.
The number of patients with a particular level of vision may be a better mark of the success of treatment for neovascular age-related macular degeneration than the gain or loss of letters able to be seen in logMAR chart testing, suggest researchers.
Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from its ongoing AZX100 Phase 2a clinical trial in trocar site scarring following arthroscopic shoulder surgery. Based on this analysis, the clinical trial will continue to its planned 12-month endpoints.
› Verified 6 days ago
| NPI Number | 1407950256 |
| Organization Name | CVS ALBANY LLC |
| Doing Business As | CVS PHARMACY#2595 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 722 Dutchess Tpke, Poughkeepsie, NY 12603 |
| Phone Number | 845-452-7117 |
News Archive
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
Included in the 2012 International Antiviral Society-USA panel recommendations for human immunodeficiency virus (HIV) patient care is that all adult patients, regardless of CD4 cell count, should be offered antiretroviral therapy (ART), according to an article in the July 25 issue of JAMA, a theme issue on HIV/AIDS.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, today will participate in the first international bell-ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and future challenges in the battle to eradicate polio at the stock exchanges in New York, Paris, Brussels, Amsterdam and Lisbon.
The number of patients with a particular level of vision may be a better mark of the success of treatment for neovascular age-related macular degeneration than the gain or loss of letters able to be seen in logMAR chart testing, suggest researchers.
Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from its ongoing AZX100 Phase 2a clinical trial in trocar site scarring following arthroscopic shoulder surgery. Based on this analysis, the clinical trial will continue to its planned 12-month endpoints.
› Verified 6 days ago
News Archive
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
Included in the 2012 International Antiviral Society-USA panel recommendations for human immunodeficiency virus (HIV) patient care is that all adult patients, regardless of CD4 cell count, should be offered antiretroviral therapy (ART), according to an article in the July 25 issue of JAMA, a theme issue on HIV/AIDS.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, today will participate in the first international bell-ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and future challenges in the battle to eradicate polio at the stock exchanges in New York, Paris, Brussels, Amsterdam and Lisbon.
The number of patients with a particular level of vision may be a better mark of the success of treatment for neovascular age-related macular degeneration than the gain or loss of letters able to be seen in logMAR chart testing, suggest researchers.
Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from its ongoing AZX100 Phase 2a clinical trial in trocar site scarring following arthroscopic shoulder surgery. Based on this analysis, the clinical trial will continue to its planned 12-month endpoints.
› Verified 6 days ago
Clinical Prosthetics & Orthotics Ll Type: Prosthetic/Orthotic Supplier Location: 7 Mansion Street, Poughkeepsie, New York 12601 Phone: (845) 486-1060 | |
Cvs Pharmacy # 02595 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 722 Dutchess Tpke, Poughkeepsie, New York 12603 Phone: (845) 452-7117 | |
Cvs Pharmacy #00418 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2503 South Rd, Poughkeepsie, New York 12601 Phone: (845) 462-2791 | |
Cvs Pharmacy #16976 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2001 South Rd, Poughkeepsie, New York 12601 Phone: (845) 297-3852 | |
Rite Aid Pharmacy #10714 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3350 North Rd, Poughkeepsie, New York 12601 Phone: (845) 452-6153 |